News Center
Share the latest news with you
IMS reported IMPACT Therapeutics in its R&D FOCUS drug news
2011-12-20
IMSDRUGNEWS has a two-page introduction of IMPACT Therapeutics and IMPACT’s three ongoing oncology programs, in the Dec.19th, 2011(Volume 20, No.51) issue of R&D FOCUS drugnews.
About IMPACT
Founded in 2009, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases. Since its inception, IMPACT has successfully built a new and effective scientific and business model and made tremendous progress in three oncology drug discovery areas: Microtubule Inhibitors, PARP-1 Inhibitors, and Hedgehog Pathway Inhibitors.
About IMSDRUGNEWS
The (IMS R&D FOCUS drug news) is a weekly publication from IMS LifeCycle. It includes reports on new drug launches, approvals, licensing, and company focus.
IMSDRUGNEWS is especially useful to evalsuate new research developments on drugs and pharmaceuticals, and to locate the latest news concerning research and development trends and ideas.
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 苏ICP备 60370209号 苏公网安备 32011202000351 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
